To see if your product is a good candidate for the botanical drug IND development
Dantonic® (T89) Capsule to Prevent and Treat Stable Angina (CAESA)
Developed form a formulated Chinese Traditional Medicine (TCM) herb, Dantonic® (T89) is a botanical drug consists of extracts from 5 herbs including Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng) with borneol in a capsule form. It is indicated for angina pectoris.
A Hemp Product-X for Treating Cancer
A hemp product, mixture of cannabis product and other botanical products by removing THC, is now on early stage of the US FDA ND process. The product is indicated for oncology.
XueZhiKang (XZK) in Patients With Hyperlipidemia
Xue Zhi Kang (XZK) is a formulated traditional chinese medicine (TCM) product. It is an extract from fermented red yeast rice. It passed US FDA phase 1 and phase 2 clinical trials with demonstrated safety and lipid-lowering effect for patients with Hyperlipidemia.
A Hemp Product-Y for Pre-Diabetics and Type II Diabetics
CBD is a non-psychoactive part of the cannabis plant and is believed to have numerous medicinal benefits, including but not limited to relieving symptoms of seizure disorders and relieving inflammation, anxiety, and nausea. Cannabidivarin (CBDV) is a homologue of CBD, a rare cannabinoid. Research revolving around CBDV is in its beginning stages but gaining momentum. While lesser known than its cousin cannabinoid, CBDV is very promising in its advantageous medicinal effects.